{"id":"NCT03830333","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","officialTitle":"A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-20","primaryCompletion":"2020-10-14","completion":"2020-10-14","firstPosted":"2019-02-05","resultsPosted":"2021-10-22","lastUpdate":"2023-01-17"},"enrollment":268,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Complicated Intra-abdominal Infections"],"interventions":[{"type":"DRUG","name":"Ceftolozane/Tazobactam","otherNames":["MK-7625A"]},{"type":"DRUG","name":"Metronidazole","otherNames":[]},{"type":"DRUG","name":"Meropenem","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ceftolozane/Tazobactam + Metronidazole","type":"EXPERIMENTAL"},{"label":"Meropenem + Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This study aims to evaluate the efficacy of ceftolozane/tazobactam (MK-7625A) plus metronidazole versus meropenem in adults diagnosed with complicated intra-abdominal infection (cIAI). The primary hypothesis is ceftolozane/tazobactam plus metronidazole is non-inferior to meropenem, as measured by the clinical response rate at the Test-of Cure (TOC) visit in the Clinically Evaluable (CE) population.","primaryOutcome":{"measure":"Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population","timeFrame":"Up to approximately Day 30","effectByArm":[{"arm":"Ceftolozane/Tazobactam + Metronidazole","deltaMin":95.2,"sd":null},{"arm":"Meropenem + Placebo","deltaMin":93.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":25,"countries":["China"]},"refs":{"pmids":["35987467","40913503"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":134},"commonTop":["Pyrexia","Diarrhoea","Cough","Constipation","Hypokalaemia"]}}